文献速递免疫规划

婴儿出生时接种单价乙肝疫苗后,2、4、6和18月龄接种五价DTwP-HB-Hib与六价DTaP-HB-Hib-IPV疫苗诱导的乙肝表面抗体水平比较

Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth.
PubMed 文献 · Vaccine · 2020-01-14

在泰国,婴儿出生时接种单价乙肝疫苗后,随机接种五价DTwP-HB-Hib或六价DTaP-HB-Hib-IPV疫苗,并在2、4、6和18月龄接种。完成四剂免疫后,两组抗-HBs≥10 mIU/ml的比例均为99.2%;18月龄加强后,六价组100%、五价组99.2%;24月龄时六价组98.3%高于五价组86.5%。两种疫苗均能有效诱导抗-HBs≥10 mIU/ml,均可作为18月龄单剂加强以简化免疫规划接种。

要点

  • 四剂免疫后抗-HBs≥10 mIU/ml比例:六价组99.2%、五价组99.2%、EPI五价组98.5%。
  • 18月龄加强后抗-HBs≥10 mIU/ml比例:六价组100%、五价组99.2%、EPI五价组93.8%。
  • 24月龄时抗-HBs≥10 mIU/ml比例:六价组98.3%高于五价组86.5%。

核心结论

  • 两种疫苗均能有效诱导抗-HBs水平≥10 mIU/ml,因此均可作为18月龄单剂加强以简化泰国扩大免疫规划下的接种。

研究设计与样本

  • 两组婴儿的母亲既往接种过破伤风-白喉-无细胞百日咳疫苗(Tdap),出生时接种单价乙肝疫苗后,随机在2、4、6和18月龄接种五价DTwP-HB-Hib或六价DTaP-HB-Hib-IPV疫苗。
  • 第三组婴儿的母亲未接种Tdap,接种DTwP-HB-Hib(EPI五价组)。
  • 在出生时、基础免疫后1个月(第7月龄)、加强前(第18月龄)、加强后1个月(第19月龄)和加强后6个月(第24月龄)采集血样。
  • 采用自动化化学发光微粒子免疫分析法检测HBsAg、抗-HBc和抗-HBs水平。

主要发现

  • 完成四剂免疫(0、2、4、6月龄)后,抗-HBs≥10 mIU/ml的比例分别为六价组99.2%、五价组99.2%、EPI五价组98.5%。
  • 18月龄额外剂量后1个月,抗-HBs≥10 mIU/ml的比例分别为六价组100%、五价组99.2%、EPI五价组93.8%。
  • 24月龄时,抗-HBs≥10 mIU/ml的比例六价组为98.3%,五价组为86.5%。

关键数值与推荐

  • 四剂免疫后抗-HBs≥10 mIU/ml:六价组99.2%、五价组99.2%、EPI五价组98.5%。
  • 18月龄加强后1个月抗-HBs≥10 mIU/ml:六价组100%、五价组99.2%、EPI五价组93.8%。
  • 24月龄抗-HBs≥10 mIU/ml:六价组98.3% vs 五价组86.5%(六价组较高)。

临床怎么用

  • 两种疫苗均能有效诱导抗-HBs≥10 mIU/ml,均可作为18月龄单剂加强以简化泰国扩大免疫规划下的接种。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Thailand, the hepatitis B (HB) vaccine is administered as a tetravalent vaccine (DTwP-HB) to all infants at 2, 4, and 6 months of age, following an initial vaccination with a monovalent HB vaccine at birth. As part of ongoing vaccine evaluation, we aimed to compare the hepatitis B immunogenicity profiles of children who had received either the pentavalent (DTwP-HB-Hib) or the hexavalent (DTaP-HB-Hib-IPV) vaccine. METHODS: Two groups of infants, whose mothers previously received the tetanus-diphtheria-acellular pertussis vaccine (Tdap), were randomly vaccinated with either pentavalent or hexavalent vaccine at 2, 4, 6, and 18 months of age, following monovalent HB vaccine at birth. Blood samples were obtained at birth, one-month post-primary series immunization (mo 7), pre-booster (mo 18), one-month post-booster (mo 19), and six months post-booster (mo 24). The third group of infants, whose mothers did not receive Tdap, was vaccinated with DTwP-HB-Hib (EPI pentavalent group). Levels of HBsAg, anti-HBc, and anti-HBs were evaluated by means of an automated Chemiluminescent Microparticle Immunoassay. RESULTS: Anti-HBs levels of ≥10 mIU/ml were achieved in 99.2% (hexavalent group), 99.2% (pentavalent group), and 98.5% (EPI pentavalent group) of infants, after four-dose immunization (at 0, 2, 4, 6 months of age). One month after the additional dose given at 18 months of age, anti-HBs levels of ≥10 mIU/ml were observed in 100% (hexavalent group), 99.2% (pentavalent group), and 93.8% (EPI pentavalent group) of infants. At 24 months of age, higher percentages of infants achieving anti-HBs levels ≥10 mIU/ml were found in the hexavalent group (98.3%) compared to the pentavalent group (86.5%). CONCLUSIONS: Both vaccines were effective in inducing anti-HBs levels of ≥10 mIU/ml, and therefore either can be used as a single formula booster at 18 months of age to simplify vaccine administration under the Expanded Program on Immunization in Thailand.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Posuwan N, Wanlapakorn N, Vongpunsawad S, et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine. 2020. PMID: 31948817. doi:10.1016/j.vaccine.2019.12.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。